BioWorld4h
Prime’s $3.61B Bristol Myers deal is year’s fourth largest
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
Bristol, Prime Medicine in deal to develop T-cell therapies
Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.
Pharmaceutical Technology12h
Modalis wins FDA rare paediatric designation for CMD CRISPR therapy
Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...
FDA approves PureTech’s KarXT to treat schizophrenia in adults
PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...
Pharmaceutical Technology18h
SK pharmteco announces $260m production expansion in South Korea
SK pharmteco, a contract development and manufacturing organisation, has announced an investment of $260m to expand its small ...